Dutch Study Highlights Benefits of Off-Label Targeted Cancer Therapies
A Dutch multicenter trial, known as the DRUP trial, has demonstrated that off-label targeted cancer therapies can benefit a broader range of patients. The trial included over 1600 patients with advanced cancers who had no remaining standard therapeutic options. The study, published in Nature, shows that about one-third of participants responded positively to treatments, with some experiencing stable disease for at least four months. Notably, 67 exceptional responders were identified, showing complete response or remaining progression-free for at least two years. The trial emphasizes the potential of off-label use of existing drugs to provide substantial benefits, particularly for patients with rare or difficult-to-treat cancers. 
